Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute of Rheumatology will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Woman holding her stomach appearing to be in pain

The intestine is one of the largest immune organs in the body. When healthy, it is regulated by a complex communication network which ensures that the intestinal immune cells peacefully co-exist with the large number of microbes that inhabit the gut.

When there is disruption to any of the communication pathways, the wall of the intestinal wall can become inflamed and inflammatory bowel diseases (IBDs), encompassing Crohn's disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDu), can develop.

There is no cure for IBD and patients can go through unpredictable periods of relapse and remission. Genes, diet and other environmental factors all play a part meaning the disease is never the same for any patient and the response to therapies can vary, with more than 1 out of 2 patients not responding to treatment in the long-term. For this reason, personalised therapies are not standard practise for IBD.

"In a previous study we were able to group patients with IBD, that do not respond well to current therapies, based on their cellular and molecular characteristics or 'pathotype'", said Professor Dame Fiona Powrie, Director of the Kennedy Institute of Rheumatology. "The MRC funding will enable us build on this work and characterise these IBD pathotypes in more detail. By understanding the pathotypes of different patient groups, we move towards being able to discover and direct new therapies to those most likely to benefit."

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.